MA34509B1 - Composé hétérocyclique et son utilisation - Google Patents

Composé hétérocyclique et son utilisation

Info

Publication number
MA34509B1
MA34509B1 MA35708A MA35708A MA34509B1 MA 34509 B1 MA34509 B1 MA 34509B1 MA 35708 A MA35708 A MA 35708A MA 35708 A MA35708 A MA 35708A MA 34509 B1 MA34509 B1 MA 34509B1
Authority
MA
Morocco
Prior art keywords
formula
heterocyclic compound
compound
isoxazolepropionic
adhd
Prior art date
Application number
MA35708A
Other languages
English (en)
Inventor
Masakuni Kori
Toshihiro Imaeda
Shinji Nakamura
Masashi Toyofuku
Eiji Honda
Yasutomi Asano
Osamu Ujikawa
Michiyo Mochizuki
Original Assignee
Takeda Pharmaceutcal Company Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutcal Company Ltd filed Critical Takeda Pharmaceutcal Company Ltd
Publication of MA34509B1 publication Critical patent/MA34509B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Composé représenté par la formule (I) : - chaque symbole dans la formule étant tel que défini dans la description, ou sel de celui-ci, ayant une action de potentialisation du récepteur AMPA (acide alpha-amino-3-hydroxy-5-méthyl- 4-isoxazolepropionique). Le composé selon la présente invention est utile à titre d'agent prophylactique ou thérapeutique pour la dépression, la schizophrénie, la maladie d'Alzheimer ou le trouble du déficit de l'attention/ hyperactivité (TDAH) et autres.
MA35708A 2010-08-10 2011-08-09 Composé hétérocyclique et son utilisation MA34509B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010179577 2010-08-10
PCT/JP2011/068497 WO2012020848A1 (fr) 2010-08-10 2011-08-09 Composé hétérocyclique et son utilisation

Publications (1)

Publication Number Publication Date
MA34509B1 true MA34509B1 (fr) 2013-09-02

Family

ID=44534564

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35708A MA34509B1 (fr) 2010-08-10 2011-08-09 Composé hétérocyclique et son utilisation

Country Status (38)

Country Link
US (10) US8575154B2 (fr)
EP (1) EP2603513B1 (fr)
JP (2) JP5788496B2 (fr)
KR (1) KR101852215B1 (fr)
CN (2) CN103180326B (fr)
AR (1) AR082618A1 (fr)
AU (1) AU2011290126B2 (fr)
BR (1) BR112013002250B1 (fr)
CA (1) CA2807460C (fr)
CL (1) CL2013000380A1 (fr)
CO (1) CO6680700A2 (fr)
CR (1) CR20130066A (fr)
CY (1) CY1123507T1 (fr)
DK (1) DK2603513T3 (fr)
DO (1) DOP2013000030A (fr)
EA (1) EA022078B1 (fr)
EC (1) ECSP13012478A (fr)
ES (1) ES2793723T3 (fr)
GE (1) GEP20156216B (fr)
HR (1) HRP20200844T1 (fr)
HU (1) HUE049460T2 (fr)
IL (1) IL224452A (fr)
LT (1) LT2603513T (fr)
MA (1) MA34509B1 (fr)
MX (1) MX349470B (fr)
MY (1) MY165908A (fr)
NZ (1) NZ607593A (fr)
PE (1) PE20131116A1 (fr)
PL (1) PL2603513T3 (fr)
PT (1) PT2603513T (fr)
RS (1) RS60311B1 (fr)
SG (1) SG187656A1 (fr)
SI (1) SI2603513T1 (fr)
TW (1) TWI504604B (fr)
UA (1) UA111594C2 (fr)
UY (1) UY33551A (fr)
WO (1) WO2012020848A1 (fr)
ZA (1) ZA201301120B (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2603513T (pt) * 2010-08-10 2020-06-08 Takeda Pharmaceuticals Co Composto heterocíclico e sua utilização como modulador alostérico positivo do recetor de ampa
JP5976011B2 (ja) * 2011-04-05 2016-08-23 武田薬品工業株式会社 スルホンアミド誘導体およびその用途
US9493484B2 (en) 2012-02-08 2016-11-15 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
AU2014277952A1 (en) * 2013-06-13 2016-01-28 Veroscience Llc Compositions and methods for treating metabolic disorders
RS59018B1 (sr) 2013-06-27 2019-08-30 Pfizer Heteroaromatična jedinjenja i njihova upotreba kao dopamin d1 liganada
US11589583B2 (en) 2013-12-03 2023-02-28 Fmc Corporation Pyrrolidinones herbicides
DK3077374T3 (da) 2013-12-03 2020-05-04 Fmc Corp Pyrrolidinoner som herbicider
MX2016017251A (es) 2014-07-02 2017-04-27 Du Pont Herbicidas de piperidinona.
MX2017007087A (es) 2014-12-08 2017-09-05 Du Pont 3-oxo-3-(arilamino)propanoatos, proceso para su preparacion y su uso en la preparacion de pirrolidinonas.
JP6956637B2 (ja) 2015-04-10 2021-11-02 エフ エム シー コーポレーションＦｍｃ Ｃｏｒｐｏｒａｔｉｏｎ 除草剤としての置換環状アミド
EP3288928B1 (fr) 2015-04-27 2021-10-13 FMC Corporation Butyrolactones comme herbicides
WO2016176460A1 (fr) * 2015-04-29 2016-11-03 Janssen Pharmaceutica Nv Azabenzimidazoles et leur utilisation en tant que modulateurs des récepteurs ampa
KR20170141768A (ko) * 2015-04-29 2017-12-26 얀센 파마슈티카 엔.브이. 이미다조피라진 및 피라졸로피리미딘 및 ampa 수용체 조절제로서의 이의 용도
EP3650430A1 (fr) 2015-05-12 2020-05-13 FMC Corporation Produits intermediare et procedés pour la synthese de herbicides
WO2016196019A1 (fr) 2015-05-29 2016-12-08 E I Du Pont De Nemours And Company Amides cycliques substitués utilisés comme herbicides
JP6949730B2 (ja) 2015-06-02 2021-10-13 エフ エム シー コーポレーションＦｍｃ Ｃｏｒｐｏｒａｔｉｏｎ 置換環状アミドおよび除草剤としてのそれらの使用
JP6937290B2 (ja) 2015-07-31 2021-09-22 エフ エム シー コーポレーションＦｍｃ Ｃｏｒｐｏｒａｔｉｏｎ 除草剤として有用な環状ｎ−カルボキサミド化合物
TW201713774A (zh) 2015-08-06 2017-04-16 Kohjin Life Sciences Co Ltd 含有β-菸鹼醯胺單核苷酸的酵母萃取物及其製造方法
MX369556B (es) * 2015-08-06 2019-11-12 Hoffmann La Roche Procesos para la preparacion de derivados acidos de n-acetilgalactosamina (galnac).
US20170181292A1 (en) * 2015-12-16 2017-06-22 Rohm And Haas Electronic Materials Llc Method for forming organic coating on nickel surface
CN105669731B (zh) * 2016-01-10 2017-06-30 沧州普瑞东方科技有限公司 一种4‑(4‑烷基环己氧基)苯硼酸的合成方法
AU2017378640B2 (en) 2016-12-21 2022-03-03 Fmc Corporation Nitrone herbicides
CN107892697B (zh) 2016-12-26 2020-11-03 郑州泰基鸿诺医药股份有限公司 一种[1,3]噻嗪-2-胺类化合物及应用，药物组合物
WO2018175226A1 (fr) 2017-03-21 2018-09-27 Fmc Corporation Pyrrolidinones et procédé pour les préparer
UA126576C2 (uk) 2017-03-21 2022-11-02 ЕфЕмСі КОРПОРЕЙШН Гербіцидна суміш, композиція та спосіб
AR111839A1 (es) 2017-05-30 2019-08-21 Fmc Corp Lactamas 3-sustituidas herbicidas
AR111967A1 (es) 2017-05-30 2019-09-04 Fmc Corp Amidas herbicidas
EP3693360B1 (fr) * 2017-10-06 2023-12-13 Takeda Pharmaceutical Company Limited Composés hétérocycliques
WO2019070043A1 (fr) 2017-10-06 2019-04-11 武田薬品工業株式会社 Composé hétérocyclique
WO2021229294A1 (fr) 2020-05-15 2021-11-18 Takeda Pharmaceutical Company Limited Traitement de la dépression

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0437742Y2 (fr) 1986-10-22 1992-09-04
JPH0285851A (ja) 1988-09-22 1990-03-27 Konica Corp 新規な写真用カプラー
JPH037742A (ja) 1989-06-05 1991-01-14 Toyo Tire & Rubber Co Ltd ラバーチエーン用ゴム組成物
JP2874960B2 (ja) 1990-06-03 1999-03-24 コニカ株式会社 新規な染料を含有するハロゲン化銀写真感光材料
JPH04119890A (ja) * 1990-09-11 1992-04-21 Konica Corp ピラゾロチアジアジン系色素
JP3430375B2 (ja) * 1993-11-12 2003-07-28 コニカ株式会社 感熱転写材料及び該材料に好適な色素
DE19704923A1 (de) 1997-02-10 1998-08-13 Hoechst Schering Agrevo Gmbh Klebstoffhaltige Schädlingsbekämpfungsmittel
BR0015510A (pt) 1999-11-04 2004-02-25 Univ Colorado State Res Found Método e dispositivo para atrair insetos
FR2801587B1 (fr) 1999-11-30 2002-01-11 Adir Nouveaux derives de benzothiadiazines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP1436270A1 (fr) 2001-10-10 2004-07-14 Neurosearch A/S Nouveaux derives de benzothiazine, leur preparation et leur utilisation
FR2833955B1 (fr) 2001-12-21 2004-01-30 Servier Lab Nouveaux derives de benzothiazine et de benzothiadiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2854634B1 (fr) * 2003-05-05 2005-07-08 Servier Lab Nouveaux derives de thiadiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2865474B1 (fr) 2004-01-26 2008-06-13 Servier Lab Nouveaux derives de benzothiazines fluorees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2879201B1 (fr) 2004-12-10 2007-02-16 Servier Lab Nouveaux derives de benzothiazine et benzothiadiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CA2655376A1 (fr) 2006-06-23 2007-12-27 Nufarm Australia Limited Composition herbicide de phenoxy-alcanoate et procede de preparation et utilisation
AU2007333247B2 (en) * 2006-12-11 2012-06-07 Eli Lilly And Company AMPA receptor potentiators
US20080167374A1 (en) 2007-01-09 2008-07-10 Loveland Products, Inc. Pesticide composition and method of use
JP2011503002A (ja) * 2007-11-05 2011-01-27 シェーリング コーポレイション γセクレターゼ調節剤
EP2219646A4 (fr) * 2007-12-21 2010-12-22 Univ Rochester Procédé permettant de modifier la durée de vie d'organismes eucaryotes
EP2269990A4 (fr) 2008-03-25 2012-04-18 Takeda Pharmaceutical Composé hétérocyclique
JP2009248543A (ja) 2008-04-11 2009-10-29 Fujifilm Corp 光情報記録媒体および情報記録方法
TW201012803A (en) 2008-06-06 2010-04-01 Organon Nv Heterocyclic derivatives
AU2009313538A1 (en) * 2008-11-06 2010-05-14 Merck Sharp & Dohme Corp. Gamma secretase modulators
TW201030002A (en) 2009-01-16 2010-08-16 Bristol Myers Squibb Co Bicyclic compounds for the reduction of beta-amyloid production
JP2012051806A (ja) 2009-02-26 2012-03-15 Eisai R & D Management Co Ltd イミダゾリルピラジン誘導体
FR2943342B1 (fr) 2009-03-20 2011-03-04 Servier Lab Nouveaux derives de benzothiadiazepines,leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
WO2010140339A1 (fr) 2009-06-01 2010-12-09 武田薬品工業株式会社 Composé hétérocyclique
JPWO2011007756A1 (ja) 2009-07-13 2012-12-27 武田薬品工業株式会社 複素環化合物及びその用途
WO2011036889A1 (fr) 2009-09-25 2011-03-31 武田薬品工業株式会社 Composé hétérocyclique
WO2011036885A1 (fr) 2009-09-25 2011-03-31 武田薬品工業株式会社 Composé hétérocyclique
PT2603513T (pt) * 2010-08-10 2020-06-08 Takeda Pharmaceuticals Co Composto heterocíclico e sua utilização como modulador alostérico positivo do recetor de ampa

Also Published As

Publication number Publication date
US9884875B2 (en) 2018-02-06
HUE049460T2 (hu) 2020-09-28
EA201390222A1 (ru) 2013-08-30
RS60311B1 (sr) 2020-07-31
BR112013002250A2 (pt) 2016-05-24
EP2603513B1 (fr) 2020-03-11
PE20131116A1 (es) 2013-10-24
NZ607593A (en) 2015-01-30
US20170022222A1 (en) 2017-01-26
DOP2013000030A (es) 2013-03-15
BR112013002250B1 (pt) 2020-10-27
US20130184266A1 (en) 2013-07-18
US20150073137A1 (en) 2015-03-12
TW201217386A (en) 2012-05-01
US20150353578A1 (en) 2015-12-10
US20180162875A1 (en) 2018-06-14
CY1123507T1 (el) 2022-03-24
AU2011290126B2 (en) 2016-01-07
CO6680700A2 (es) 2013-05-31
MY165908A (en) 2018-05-18
JP2013535408A (ja) 2013-09-12
TWI504604B (zh) 2015-10-21
JP6113789B2 (ja) 2017-04-12
JP2016006080A (ja) 2016-01-14
SG187656A1 (en) 2013-03-28
US8916551B2 (en) 2014-12-23
HRP20200844T1 (hr) 2020-08-21
US9499568B2 (en) 2016-11-22
CN103180326A (zh) 2013-06-26
US20130190291A1 (en) 2013-07-25
CN104926837A (zh) 2015-09-23
ES2793723T3 (es) 2020-11-16
ECSP13012478A (es) 2013-04-30
EA022078B1 (ru) 2015-10-30
CN103180326B (zh) 2015-06-10
US10654874B2 (en) 2020-05-19
SI2603513T1 (sl) 2020-07-31
UA111594C2 (uk) 2016-05-25
ZA201301120B (en) 2014-04-30
DK2603513T3 (da) 2020-06-15
PT2603513T (pt) 2020-06-08
US8575154B2 (en) 2013-11-05
UY33551A (es) 2012-03-30
MX349470B (es) 2017-07-31
MX2013001614A (es) 2013-07-05
KR101852215B1 (ko) 2018-04-25
US11279713B2 (en) 2022-03-22
US9150591B2 (en) 2015-10-06
CL2013000380A1 (es) 2013-05-31
PL2603513T3 (pl) 2020-07-27
IL224452A (en) 2017-11-30
US8778934B2 (en) 2014-07-15
LT2603513T (lt) 2020-05-25
US20120077799A1 (en) 2012-03-29
KR20130138738A (ko) 2013-12-19
GEP20156216B (en) 2015-01-12
US20140080817A1 (en) 2014-03-20
US20200317692A1 (en) 2020-10-08
US20190263832A1 (en) 2019-08-29
EP2603513A1 (fr) 2013-06-19
WO2012020848A8 (fr) 2012-09-27
WO2012020848A1 (fr) 2012-02-16
AR082618A1 (es) 2012-12-19
AU2011290126A1 (en) 2013-03-07
CA2807460C (fr) 2018-09-18
JP5788496B2 (ja) 2015-09-30
CR20130066A (es) 2013-05-03
CA2807460A1 (fr) 2012-02-16

Similar Documents

Publication Publication Date Title
MA34509B1 (fr) Composé hétérocyclique et son utilisation
MA31759B1 (fr) Compose amide
MA33275B1 (fr) Inhibiteurs de la replication du virus de l'immunodeficience humaine
MA47217B1 (fr) Composés de n-((hét)arylméthyl)hétéroaryle-carboxamides en tant qu'inhibiteurs de la kallicréine plasmatique
MA35364B1 (fr) Dérivés hétérocycliques bicycliques pour le traitement d'une hypertension artérielle pulmonaire
MA32171B1 (fr) Compose heterocyclique
MA33420B1 (fr) Dérivés fluorés de l'aminotriazole
MA35434B1 (fr) Amino-quinazolines en tant qu'inhibiteurs de kinase
MA38390A1 (fr) Composés tétrahydropyrrolothiazines
MA33209B1 (fr) Inhibiteurs de la replication du virus de l'hepatite c
MA33492B1 (fr) Inhibiteurs de bace
MA37142A3 (fr) Dérivés de dihydro-benzo-oxazine et de dihydro-pyrido-oxazine
PE20181378A1 (es) Compuestos biciclicos derivados de dihidroquinolina-2-ona como inhibidores de cyp11b
MA32104B1 (fr) Dérivés d'oxime en tant qu'inhibiteurs de hsp90
MA34361B1 (fr) Dérivés de tétrahydro-pyrido-pyrimidine
MA46101B1 (fr) Modulateurs allostériques positifs du récepteur muscarinique m1
MA38403A1 (fr) Nouveaux dérivés de pyrazole modulateurs specifiques de cb2
MA37891A1 (fr) Alcoxypyrazoles comme activateurs de guanylate cyclase soluble
MA35104B1 (fr) Inhibiteur du virus de l'hepatite c
MA38410B1 (fr) Composés d'azétidinyloxyphénylpyrrolidine
BR112013004624A2 (pt) "derivados de furopiridina"
MA34098B1 (fr) Utilisation de nouveaux inhibiteurs pan-cdk pour le traitement de tumeurs
MA30341B1 (fr) Dérivés de benzimidazole
MA32985B1 (fr) Nouveaux microbiocides
MA38307A1 (fr) 4-hydroxy-2-méthyl-5-(propan-2-ylidène)cyclohex-3-ènecarbaldéhyde pour la prévention et le traitement d'une maladie cognitive, neurodégénérative ou neuronale